Latest news with #SuvenLifeSciences
&w=3840&q=100)
Business Standard
7 days ago
- Business
- Business Standard
2 smallcaps zoom up to 153% from April low. What's driving these stocks?
Share price of Suven Life Sciences, Camlin Fine Sciences today Shares of Suven Life Sciences (Suven) and Camlin Fine Sciences (CFSL) hit their respective new highs, surging up to 9 per cent on the BSE in Monday's intra-day trade. The stock price of both these smallcap companies have outperformed the market, by zooming up to 153 per cent from their April month lows. On April 7, 2025, the market including BSE Sensex, BSE Midcap and BSE Smallcap indices recorded their respective 52-week lows. Individually, Suven has rallied 9 per cent to ₹257.70 in intra-day trade today. In the past one month, the market price of the healthcare research, analytics & technology company has surged 36 per cent. It has bounced back 124 per cent from its April 7, 2025 low of ₹115 on the BSE. Shares of Camlin soared 7 per cent to ₹324.20, surging 67 per cent in the past one month. The stock price of this specialty chemicals makee has zoomed 153 per cent from a level of ₹128.10 touched on April 7, 2025. What's driving Suven, Camlin stock prices? CFLS reported a strong operational performance for the March 2025 quarter (Q4FY25). The company reported 88.7 per cent year-on-year (YoY) growth in earnings before interest, taxes, depreciation and amortisation (EBITDA) from its continuing operations at ₹59.41 crore, as against ₹31.48 crore in Q4FY24. Reported EBITDA margins expanded to 13.6 per cent from 8.4 per cent from the year ago quarter. Revenue from operations grew 16.1 per cent YoY to ₹437.46 crore from ₹376.65 crore. Profit after tax (PAT) increased 16.9 per cent YoY at ₹22.74 crore. At the consolidated level, CFSL derives around 85 per cent of its revenue from exports and from overseas subsidiaries, with over 100 products sold in around 80 countries. The company caters to diverse end user industries such as food, feed, animal and pet nutrition, flavours and fragrances, pharma, agrochemicals, and petrochemicals among others. This helps the company avoid dependence on any single industry and provides potential for expansion. Management anticipates sustained momentum in this segment, projecting a compounded annual growth rate (CAGR) of ~20 per cent over the next 2–3 years. Margins are expected to expand further as the bleeding from continued operations reduces and other operations grow. Camlin is also set to benefit from the implementation of anti-dumping measures in the US and improving Vanillin prices. While steady performance improvement is expected, the analysts remain cautious of near-term uncertainties related to tariffs and capacity ramp-up. Suven, a bio-pharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. On May 13, the board of directors of Suven approved fund raising of ₹857.64 crore through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programs and general corporate purposes and CAPEX for creating new R&D facilities. Suven has a significant opportunity in the rapidly growing CNS segment. The segment has limited competition due to high associated risks. CNS diseases include a broad spectrum of disorders in which the brain or spinal cord functioning is diminished or impaired, resulting in diminished motor, sensory, or cognitive performance. The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis and depression, drives the demand for effective CNS therapeutics. Furthermore, the pandemic has resulted in increased stress levels, anxiety, depression and other mental conditions. This has led to an increased demand for CNS therapies. Suven continues its R&D programs focused on CNS disease disorders and has secured 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and the US.
Mint
04-06-2025
- Business
- Mint
₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?
Multibagger Suven Life Sciences share price in focus: Suven Life Sciences share price has been making significant strides on Dalal Street. Despite frontline indices trading in a narrow range, the biopharmaceutical company has delivered stellar gains to its shareholders in a very short period Over the last 22 trading sessions, Suven Life Sciences has surged from ₹ 120 to ₹ 238 apiece, marking a sharp rise of 98.3%. The stock ended May with an impressive 92% monthly gain — its best performance since December 2020, when it had rallied 95%. Several factors have contributed to this sharp uptrend, with one of the key drivers being the company's recently raised ₹ 857 crore through a preferential issue. In mid-May, the company's board approved the issue of 6.4 crore fully convertible warrants on a preferential basis to promoters and non-promoter entities, each priced at ₹ 134. The funds raised will support various initiatives, including ongoing R&D efforts, clinical trials, general corporate purposes, and the development of a new research facility focused on CNS (central nervous system) therapies. Additionally, investor sentiment remains positive due to the company's strong clinical pipeline. Suven Life Sciences is currently advancing multiple CNS-focused drug candidates through various stages of clinical trials—Phases 1, 2, and 3—for conditions such as Alzheimer's disease, narcolepsy, major depressive disorder, and cognitive impairment. Despite the company's posting widening losses in the March quarter, investors remain optimistic about the company's long-term growth prospects. The company's emphasis on developing novel therapeutics for neurodegenerative disorders and CNS diseases, backed by the new fundraising, reinforces its potential for long-term growth, attracting investor interest. For the March-ending quarter, the company reported a widening of consolidated net loss to ₹ 43.95 crore from ₹ 27 crore in Q4FY24, hit by a dip in revenue and higher expenses. Its consolidated revenue from operations in the quarter under review stood at ₹ 1.47 crore against ₹ 2.39 crore in the year-ago period, it added. Total expenses in the March quarter were higher at ₹ 46.63 crore as compared to ₹ 34.21 crore in the same period a year ago. In fiscal year 2024-25, consolidated net loss widened to ₹ 160.75 crore from ₹ 105.08 crore in the previous fiscal year, while the consolidated revenue from operations in FY25 stood at ₹ 6.66 crore as compared to ₹ 11.69 crore in FY24, the company said. The company, in its earnings filing, said that it continues the R&D programs focused on central nervous system (CNS) disease disorders and granted 20 patents during the period covering the countries of Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa, and the USA. Suven, a biopharmaceutical company, is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs globally. The company has a portfolio of advanced-stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), schizophrenia, pain disorders, and gastrointestinal disorders.
India.com
02-06-2025
- Business
- India.com
India's oldest billionaire is 91 years old, has a massive net worth of Rs 130000000000, no match to Mukesh Ambani, Gautam Adani, name is...
Mukesh Ambani and Gautam Adani- File image India's oldest female billionaire: You must have heard about many billionaires who work hard day in and day out to earn their massive wealth. From Mukesh Ambani to Gautam Adani and Shiv Nadar, India has seen many billionaires who transformed their business and reached new heights. However, have you ever thought about who is the oldest billionaire of India? Moreover, would you believe if we tell you that India's oldest billionaire is 91 years old and has a massive net worth of $1.5 billion. India's oldest female billionaire Hailing from Hyderabad, Subbamma Jasti recently made headlines as India's oldest female billionaire after she got placed on the Forbes list with a massive net worth of $1.5 billion (Rs 130000000000). Currently ranked at 2358th on the Forbes billionaire list in the world, billionaire Subbamma inherited the assets of her husband Subba Rao Jasti, who died in February 2023. Story behind the wealth of Subbamma Jasti As per media reports, Subba Rao's wealth came from his stake sale of Suven Pharmaceuticals and Suven Life Sciences, both of which are run by Subba Rao and Subbamma Jasti's son Venkateswarlu Jasti. Subbamma Jasti's son, Venkateswarlu Jasti — the former Chairman and Managing Director of Suven Pharma and currently serving as an Advisor to the company — operated a chain of six community pharmacies across New York and New Jersey during the 1970s and 1980s.
Economic Times
29-05-2025
- Business
- Economic Times
Smallcap mania is back. But do Q4 earnings really justify the multibagger hype?
A blistering rally in smallcap stocks is reigniting investor dreams of overnight riches but the numbers are telling a far more complicated story. With the BSE Smallcap Index up nearly 10% in one month, retail participation is surging, echoing the speculative fervor of the last bull market that climaxed in September 2024. And the excitement isn't just index-level: in the last one month, a staggering 69 smallcap stocks have delivered over 30% returns. Among the biggest gainers, Suven Life Sciences surged 83%, while GRSE, Timex, IFCI, Nelcast, and HLE Glascoat all rallied at least 50%. ADVERTISEMENT But while prices soar, fundamentals remain shaky and earnings aren't keeping pace with the hype. 'Indian smallcaps and midcaps seem to have outperformed largecaps in Q4 FY25, but the numbers tell a different story,' said Akshay Badjate, Fund Manager at Merisis PMS. 'Our analysis of the top 750 listed companies shows smallcaps lagging in profit growth, with a median PBT growth of just 4% compared to 11% for the top 250 largecaps. Many smallcaps even posted flat or negative growth, undermining the narrative of a broad-based rally.' Despite the tepid performance on the bottom line, investor appetite has remained insatiable. The Nifty Smallcap 250 has rallied 9% in the last two months, triple the 3% rise seen in the Nifty 50. Badjate attributes this surge to 'liquidity, retail enthusiasm, and domestic growth optimism,' but warns that the disconnect between price and performance may not be sustainable.'Our view at Merisis Advisors is cautious,' he said. 'While select smallcaps with strong fundamentals remain appealing, the segment risks a correction if earnings don't align with valuations. We're trimming smallcap exposure and leaning into largecaps and large midcaps, where we see better operational momentum and value.' Also read | Rs 7 lakh crore boom in just 10 days! Is the smallcap stocks party getting out of hand? ADVERTISEMENT Q4 did deliver a few bright spots for the broader market. 'The Nifty Midcap 150 reported 15% YoY profit growth and the Smallcap 250 delivered 12%. Margin performance was largely stable in midcaps, though smallcaps saw some pressure,' said Krishna Appala, Fund Manager at Capitalmind Appala also flagged that the earnings catch-up story has its limits. 'Valuations remain stretched — midcaps trade at 34x and smallcaps at 32x trailing earnings, well above the 22x seen in largecaps. The divergence between earnings and valuations in the broader market calls for greater selectivity.' ADVERTISEMENT He further added that while largecaps may appear sluggish, they now offer a better risk-reward profile. 'Despite the sharp upmove recently, largecaps currently offer a better balance of earnings visibility and valuation comfort on a forward-looking basis. The environment today rewards fundamentals and discipline over broad-based exposure — especially when mid and smallcap multiples leave little room for error.'Still, not all fund managers are ready to write off smallcaps just yet. Vaibhav Chugh, Director and Head of Sales at Whiteoak Capital AMC, sees rich opportunity in the chaos — provided investors pick wisely. ADVERTISEMENT 'Yes, the result season started slow but as it progressed, midcaps and smallcaps have surprised on growth trajectory as well as upgrades to downgrades statistics,' Chugh said. 'We continue to be overweight small caps. We find relatively high alpha opportunities due to the heterogeneity of business models, sectors and sub-sectors in the smallcap space — which is the ideal setup for bottom-up stock pickers.' With nearly 70 smallcap names delivering eye-popping returns in a matter of weeks, the lure of the next multibagger is proving hard to resist. But experts caution that investors need to tread carefully — the fundamentals are not as broad-based as the rally suggests, and elevated valuations leave little room for disappointment. The smallcap story is far from over, but chasing momentum without earnings to back it could lead to painful lessons. Also read | Sensex soars 10,000 points from April lows. But India Inc's Q4 numbers expose cracks in market rally (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
29-05-2025
- Business
- Time of India
Smallcap mania is back. But do Q4 earnings really justify the multibagger hype?
A smallcap rally is exciting investors, with the BSE Smallcap Index rising nearly 10% in a month and many stocks delivering over 30% returns. However, earnings growth lags behind, with smallcaps showing lower profit growth compared to largecaps. Experts advise caution, suggesting a focus on fundamentals and a potential shift towards largecaps due to stretched valuations in the smallcap segment. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A blistering rally in smallcap stocks is reigniting investor dreams of overnight riches but the numbers are telling a far more complicated story. With the BSE Smallcap Index up nearly 10% in one month, retail participation is surging, echoing the speculative fervor of the last bull market that climaxed in September 2024. And the excitement isn't just index-level: in the last one month, a staggering 69 smallcap stocks have delivered over 30% returns. Among the biggest gainers, Suven Life Sciences surged 83%, while GRSE Nelcast , and HLE Glascoat all rallied at least 50%.But while prices soar, fundamentals remain shaky and earnings aren't keeping pace with the hype.'Indian smallcaps and midcaps seem to have outperformed largecaps in Q4 FY25, but the numbers tell a different story,' said Akshay Badjate, Fund Manager at Merisis PMS. 'Our analysis of the top 750 listed companies shows smallcaps lagging in profit growth, with a median PBT growth of just 4% compared to 11% for the top 250 largecaps. Many smallcaps even posted flat or negative growth, undermining the narrative of a broad-based rally.'Despite the tepid performance on the bottom line, investor appetite has remained insatiable. The Nifty Smallcap 250 has rallied 9% in the last two months, triple the 3% rise seen in the Nifty 50. Badjate attributes this surge to 'liquidity, retail enthusiasm, and domestic growth optimism,' but warns that the disconnect between price and performance may not be sustainable.'Our view at Merisis Advisors is cautious,' he said. 'While select smallcaps with strong fundamentals remain appealing, the segment risks a correction if earnings don't align with valuations. We're trimming smallcap exposure and leaning into largecaps and large midcaps, where we see better operational momentum and value.'Q4 did deliver a few bright spots for the broader market. 'The Nifty Midcap 150 reported 15% YoY profit growth and the Smallcap 250 delivered 12%. Margin performance was largely stable in midcaps, though smallcaps saw some pressure,' said Krishna Appala, Fund Manager at Capitalmind Appala also flagged that the earnings catch-up story has its limits. 'Valuations remain stretched — midcaps trade at 34x and smallcaps at 32x trailing earnings, well above the 22x seen in largecaps. The divergence between earnings and valuations in the broader market calls for greater selectivity.'He further added that while largecaps may appear sluggish, they now offer a better risk-reward profile. 'Despite the sharp upmove recently, largecaps currently offer a better balance of earnings visibility and valuation comfort on a forward-looking basis. The environment today rewards fundamentals and discipline over broad-based exposure — especially when mid and smallcap multiples leave little room for error.'Still, not all fund managers are ready to write off smallcaps just yet. Vaibhav Chugh, Director and Head of Sales at Whiteoak Capital AMC, sees rich opportunity in the chaos — provided investors pick wisely.'Yes, the result season started slow but as it progressed, midcaps and smallcaps have surprised on growth trajectory as well as upgrades to downgrades statistics,' Chugh said. 'We continue to be overweight small caps. We find relatively high alpha opportunities due to the heterogeneity of business models, sectors and sub-sectors in the smallcap space — which is the ideal setup for bottom-up stock pickers.'With nearly 70 smallcap names delivering eye-popping returns in a matter of weeks, the lure of the next multibagger is proving hard to resist. But experts caution that investors need to tread carefully — the fundamentals are not as broad-based as the rally suggests, and elevated valuations leave little room for disappointment. The smallcap story is far from over, but chasing momentum without earnings to back it could lead to painful lessons.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
